June 1, 2019Open Access

Population-Based Study on Cancer Subtypes, Guideline-Concordant Adjuvant Therapy, and Survival Among Women With Stage I–III Breast Cancer

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Most patients received guideline-concordant AST, except for those with the HR+/HER2+ subtype. Patients receiving guideline-adherent adjuvant therapy had better survival outcomes across all breast cancer subtypes.

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Hsieh et al. (Sat,) studied this question.

synapsesocial.com/papers/69d91c7dccb0bba5a5684208 https://doi.org/https://doi.org/10.6004/jnccn.2018.7272

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Coding Algorithms for Defining Comorbidities in ICD-9-CM and ICD-10 Administrative Data2005 · 10,673 citations
2What's going on 乳癌 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group(EBCTCG). Lancet. 2005; 365: 1687-717. PMID: 15894097.--早期乳癌に対する化学療法・内分泌療法が乳癌再発・15年生存率に及ぼす効果を示した論文:無作為化比較試験のメタアナリシス2006 · 684 citations
3Survival Analysis Part I: Basic concepts and first analyses2003 · 1,032 citations
4Outcomes of her2-positive Early-Stage Breast Cancer in the Trastuzumab Era: A Population-Based Study of Canadian Patients2013 · 32 citations
5Impact of Breast Cancer Subtypes and Treatment on Survival: An Analysis Spanning Two Decades2012 · 250 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo